South Dakota built policy around 2016 guidance.The guidance changed.
South Dakota Medicaid announced a monthly dosage reduction ending at 90 MED in October 2019 and expressly tied that target to the 2016 CDC guideline. The CDC replaced that guideline in 2022. South Dakota should now publish, reassess, and modernize the operating rule.
A legacy number should not outlive its stated foundation without review.
The state may use prior authorization to examine risk and medical necessity. It should not let a 2018 implementation schedule become an unexamined treatment ceiling after the federal guidance cited to support it has been replaced.
Name the instrument before judging the effect.
Medicaid payment criteria, physician record rules, the PDMP, federal guidance, and private health system policies are separate authorities. Each burden must be traced to the body that owns it.
Medicaid pharmacy rules
South Dakota Medicaid decides when an outpatient opioid claim requires prior authorization and what evidence supports payment.
ARSD 20 47 07
The physician record rule requires documentation for chronic noncancer pain. It does not state a universal dosage ceiling.
South Dakota PDMP
The PDMP reports controlled substance prescribing and dispensing data to assist decisions. It does not replace the clinical record.
The state documented exactly how the threshold arrived.
Implementation announced
Medicaid told pharmacies and prescribers that opioid claims above a declining MED threshold would require prior authorization.
Target reached
The schedule reduced the threshold monthly from 300 MED in October 2018 to a target of 90 MED in October 2019.
Federal guidance replaced
The CDC issued a new clinical practice guideline covering acute, subacute, and chronic pain and replacing its 2016 guideline.
The Medicaid threshold is not South Dakota prescribing law.
Payment required authorization
The 2018 notice said outpatient Medicaid pharmacy claims above the applicable threshold would be denied without prior authorization. It also identified an exemption for terminal diagnoses.
Publish today’s criteria
The historical notice does not establish every criterion, exception, form, or decision rule in force in 2026. The current operating policy should be dated, versioned, and available in one patient usable place.
Authorization is not automatic tapering.
A payment review should examine the individual record. It should not presume that dosage alone proves misuse, treatment failure, or that rapid reduction is clinically appropriate.
Reopen the rule and publish the result.
- Publish the complete current Medicaid opioid coverage criteria, MED threshold, exclusions, evidence requirements, forms, reviewer qualifications, deadlines, and appeal route.
- Conduct a public review of the 2018 policy against the 2022 CDC guideline and current evidence.
- Use dosage as one risk factor and a review trigger, not an automatic reason to deny, discontinue, or pressure a rapid taper.
- Provide a prospective medical necessity exception and continuity of established therapy while a timely request or appeal is pending.
- Report approvals, denials, appeals, reversals, interruptions, taper outcomes, geographic access, and functional results without patient identifiers.
Give South Dakota text it can adopt.
An opioid dosage threshold may initiate prior authorization but shall not, standing alone, establish lack of medical necessity. The determination shall consider diagnosis, function, pain control, treatment history, adverse effects, risk, available alternatives, patient goals, and the clinical consequences of continuation or reduction.
For a recipient receiving established therapy, coverage shall continue during a timely medical necessity review or appeal unless a qualified reviewing clinician documents an immediate and particularized safety risk and an individualized transition plan.
Turn the old schedule into a current record.
Obtain the operating criteria
Collect every current opioid edit, authorization form, exception, appeal instruction, contract term, and reviewer standard.
Compare the evidence
Place the 2018 rationale beside the 2022 CDC guideline and the state’s actual approval, denial, safety, and treatment data.
Hear affected patients
Take structured testimony from Medicaid recipients, rural and tribal communities, clinicians, pharmacists, and independent reviewers.
Issue the revised rule
Publish a dated policy with individualized criteria, continuity protection, written reasons, and a practical appeal deadline.
Audit the result
Review access, function, safety, appeals, and treatment interruption every year and correct unintended harm.
Count fair decisions, not policy announcements.
Send each correction to its owner.
| Authority | Instrument | Proper request |
|---|---|---|
| Department of Social Services | Medicaid pharmacy coverage and administration | Reassess, publish, and modernize the opioid authorization policy. |
| Pharmacy and Therapeutics Committee | Drug coverage recommendations and criteria | Review the threshold against current guidance, evidence, and patient outcomes. |
| South Dakota Legislature | Medicaid oversight and appropriation | Require transparency, continuity, reporting, and meaningful medical necessity review. |
| Board of Medical and Osteopathic Examiners | ARSD 20 47 07 and professional oversight | Preserve rigorous documentation without converting it into a universal dosage ceiling. |
| Board of Pharmacy | Prescription Drug Monitoring Program | Maintain accurate access, privacy, correction, and proper interpretation. |
Keep evidence, records, and informed decisions.
Document the whole treatment
South Dakota’s physician rule requires history, examinations, testing, risk assessment, treatment details, patient instructions, progress, consultations, and the basis for continuation or termination.
Use the PDMP as information
The state describes the PDMP as a tool that aids prescribing and dispensing decisions and requires dispensers to report controlled substance prescriptions.
Good documentation should protect individualized care.
A complete record can identify risk and also demonstrate benefit, stability, failed alternatives, functional improvement, and the danger of an inappropriate interruption.
Open the controlling documents.
Precision protects the reform.
What the sources support
- South Dakota Medicaid announced a phased authorization threshold ending at 90 MED in October 2019.
- The notice tied its target and taper schedule to the 2016 CDC guideline.
- The CDC issued a replacement clinical guideline in 2022.
- South Dakota separately requires detailed medical records for physician treatment of chronic noncancer pain.
What the record does not establish
- South Dakota law forbids every prescription above 90 MED.
- The 2018 notice alone proves every opioid criterion in force today.
- A PDMP record proves misuse or determines treatment.
- Every payer or medical setting follows the Medicaid pharmacy policy.
This Atlas is public policy education and source mapping, not legal advice or individual medical advice. Patients should not abruptly change medication, refuse required procedures, or ignore clinical instructions based on this page.
When the cited guidance changes, the policy deserves review.
South Dakota can preserve careful oversight while publishing the current rule, protecting individualized medical necessity, and measuring what happens to the people subject to it.